1. CINV & PONV Overview

1.1 CINV

1.2 PONV

2. Global CINV & PONV Market

2.1 Global CINV Market Forecast by Value

2.2 Global PONV Market Forecast by Value

3. Regional CINV & PONV Market

3.1 The U.S. CINV & PONV Market Forecast by Value

3.2 The U.S. CINV & PONV Drugs Revenue by Categories

3.3 The U.S. CINV & PONV Drugs Revenue

3.3.1 The U.S. Aloxi Drug Revenue

3.3.2 The U.S. Aloxi Drug Revenue Forecast

3.3.3 The U.S. Emend Drug Revenue Forecast

3.4 The U.S. CINV Drugs Revenue

3.4.1 The U.S. Sustol Drug Revenue Forecast

3.4.2 The U.S. Cinvanti Drug Revenue Forecast

3.4.3 The U.S. Varubi Oral Drug Revenue Forecast

3.4.4 The U.S. Varubi IV Drug Revenue Forecast

3.5 The U.S. PONV Patient Population Forecast

3.6 The U.S. PONV Drugs Revenue

3.6.1 The U.S. Baremsis Drug Revenue Forecast

3.7 Europe CINV Drugs Revenue

3.7.1 Europe Varuby Oral Drug Revenue Forecast

3.7.2 Europe Varuby IV Drug Revenue Forecast

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Increasing Cancer Incidence

4.1.2 Growing Female Population

4.1.3 Increasing Pharmaceutical R&D Spending

4.1.4 Growing Healthcare Expenditure

4.1.5 Accelerating Economic Growth

4.2 Key Trends and Developments

4.2.1 Progressing Drugs under Pipeline

4.2.2 High Demand for Combination Therapy

4.2.3 Increasing Preference for Pressure Point Therapy

4.3 Challenges

4.3.1 Entry of Generics

4.3.2 Stringent Regulations

4.3.3 Treatment Cost

5. Competitive Landscape

5.1 Global Market

5.1.1 Revenue Comparison of Key Players

5.1.2 CINV & PONV Treatment Cost Comparison by Company

5.2 The U.S.

5.2.1 The U.S. CINV and PONV Market Share by Company

6. Company Profiles

6.1 Merck & Co., Inc.

6.1.1 Business Overview

6.1.2 Financial Overview

6.1.3 Business Strategies

6.2 Eisai Co., Ltd.

6.2.1 Business Overview

6.2.2 Financial Overview

6.2.3 Business Strategies

6.3 Kirin Holding Company, Limited (ProStrakan)

6.3.1 Business Overview

6.3.2 Financial Overview

6.3.3 Business Strategies

6.4 Helsinn Holding S.A.

6.4.1 Business Overview

6.4.2 Financial Overview

6.4.3 Business Strategies

List of Figures

Sub-Categories of CINV

Global CINV Market Forecast by Value (2017-2022)

Global PONV Market Forecast by Value (2017-2022)

The U.S. CINV & PONV Market Forecast by Value (2017-2022)

The U.S. CINV & PONV Drugs Revenue by Categories (2017)

The U.S. Aloxi Drug Revenue (2013-2017)

The U.S. Aloxi Drug Revenue Forecast (2018-2022)

The U.S. Emend Drug Revenue Forecast (2017-2022)

The U.S. Sustol Drug Revenue Forecast (2017-2022)

The U.S. Cinvanti Drug Revenue Forecast (2018-2022)

The U.S. Varubi Oral Drug Revenue Forecast (2018-2022)

The U.S. Varubi IV Drug Revenue Forecast (2018-2022)

The U.S. PONV Patient Population Forecast (2018-2022)

The U.S. Baremsis Drug Revenue Forecast (2019-2023)

Europe Varuby Oral Drug Revenue Forecast (2018-2022)

Europe Varuby IV Drug Revenue Forecast (2018-2022)

Global Cancer New Cases (2013-2017)

Global Female Population* (2013-2017)

Global Pharmaceutical R&D Spending (2013-2017)

Global Healthcare Expenditure (2013-2017)

Global GDP Per Capita (2013-2017)

The U.S. CINV and PONV Market Share by Company (2017)

Merck & Co., Inc. Net Sales by Business Segments (2017)

Merck & Co., Inc. Net Sales and Net Income (2013-2017)

Merck & Co., Inc. Research and Development Expenditures (2015-2017)

Eisai Co., Ltd. Revenues by Business Segments (2017*)

Eisai Co., Ltd. Revenues and Net Profit (2013-2017*)

Eisai Co., Ltd Research and Development Expenditures (2015-2017)

Kirin Holding (ProStrakan) Net Sales by Business Segments (2017)

Kirin Holding (ProStrakan) Net Sales and Net Income (Loss) (2013-2017)

Kirin Holding Company, Limited (ProStrakan) A&P Expenditures (2015-2017)

Helsinn Holding S.A. Net Sales (2013-2016)

List of Tables

Causes of PONV

Drugs under Development for CINV & PONV

Generics for CINV Therapies (2016-2018)

Key Players – Revenues Comparison (2017)

CINV & PONV Treatment Cost Comparison by Company (2018)

Helsinn Holding S.A. Drug Pipeline (2018)